RxDoctor Payments DataLook up a doctor →

Milan Shah, MD

Retina Specialist · Carmel, INNPI 1104901644

Payments from drug & device makers

$802,482in general payments, 2019–2025

Across 286 payments — averaging $2805.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$392K
  • Regeneron$341K
  • Eyepoint US, Inc.$27K
  • Bausch & Lomb Americas Inc.$13K
  • AbbVie$9K
  • Novartis$9K
  • plus $10K from 11 others
$2,628in research payments, 2019–2025

Across 10 payments — averaging $262.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K

What the payments were for

  • Consulting fees$20,07558%
  • Speaking & faculty fees$8,75825%
  • Travel & lodging$2,5077%
  • Food & beverage$3,36010%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802,482 in reported general payments places this provider in the 85th percentile of 21 retina specialist providers in Indiana.

See all retina specialist providers in Indiana

Medicare billing

Part B allowed, 2024
$2,309,690
Medicare patients
655
Services billed
16,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IlevroNepafenac138$60,546
Prednisolone Acetate272$12,954
Travoprost72$8,687
Difluprednate68$6,730
Alphagan PBrimonidine Tartrate12$5,888
VyzultaLatanoprostene Bunod11$5,230
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$4,691
LumiganBimatoprost11$4,005
ValacyclovirValacyclovir Hcl20$1,732
Ketorolac Tromethamine55$1,656
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat99$1,608
Brimonidine Tartrate72$1,163
Timolol Maleate102$1,005
Atropine Sulfate18$837
Acyclovir65$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$9,346$60,546138 claims
AbbVieAlphagan P, Lumigan$9,481$9,89323 claims
Bausch & Lomb Americas Inc.Vyzulta$13,445$5,23011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 retina specialist providers in Indiana.

Other retina specialist in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →